What are the preoperative cardiovascular assessment and medication management guidelines, including functional capacity evaluation, medication adjustments, aspirin, and anticoagulation handling, for patients undergoing surgery?

Preoperative Cardiovascular Guidelines

Continue beta blockers and statins in patients already taking them, hold ACE inhibitors/ARBs on the day of surgery, and manage antiplatelet therapy based on stent status and bleeding risk 1, 2.

Risk Stratification and Functional Capacity

The preoperative evaluation should focus on three key elements:

• Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease) require urgent evaluation and treatment before elective surgery 2
• Functional capacity assessment: Patients who can climb ≥2 flights of stairs or achieve ≥4 METs without symptoms can proceed to surgery without further testing 2, 3
• Surgery-specific risk: Low-risk procedures (e.g., cataract surgery, endoscopy) rarely require additional cardiac evaluation 2

For patients with poor functional capacity (<4 METs) and elevated risk (≥3 RCRI factors), pharmacological stress testing may be reasonable only if results will change management 2. However, routine screening with noninvasive stress testing is not useful for low-risk surgery 2.

Medication Management

Beta Blockers

Continue beta blockers in all patients currently taking them perioperatively 1, 2. This is a Class I recommendation with strong evidence.

For initiating beta blockers:

• Do NOT start beta blockers on the day of surgery (Class III: Harm) 1, 2
• May be reasonable to start in patients with ≥3 RCRI factors or intermediate/high-risk preoperative tests, but begin >1 day before surgery to assess tolerability 1, 2
• The evidence for new initiation is uncertain (Class IIb), particularly after the POISE trial showed increased stroke and mortality with high-dose perioperative beta blockade 3

Statins

Continue statins in all patients currently taking them (Class I) 1, 2. Observational data shows lower postoperative cardiovascular complications (1.8% vs 2.3%) and mortality with statin use 3.

Initiate statins in patients undergoing vascular surgery (Class IIa) 1, 2. May consider initiation in patients with clinical risk factors undergoing elevated-risk procedures 1.

ACE Inhibitors/ARBs

Continuation of ACE inhibitors or ARBs is reasonable perioperatively (Class IIa), but there is nuance here 1, 2. Many clinicians hold these medications on the day of surgery due to intraoperative hypotension risk, though the guidelines support continuation. If held, restart as soon as clinically feasible postoperatively 1.

Alpha-2 Agonists

Do not use alpha-2 agonists for prevention of cardiac events (Class III: No Benefit) 1, 2.

Antiplatelet Management

Patients WITHOUT Coronary Stents

Routine aspirin continuation or initiation is NOT beneficial in patients undergoing elective noncardiac noncarotid surgery without prior coronary stenting (Class III: No Benefit for most cases) 1, 2. The POISE-2 trial showed aspirin does not decrease cardiovascular events but increases surgical bleeding 3.

May be reasonable to continue aspirin when the risk of increased cardiac events outweighs the risk of increased bleeding (Class IIb), but this is a narrow indication 1, 2.

Patients WITH Coronary Stents

This is the most critical area requiring careful timing:

Timing of elective surgery after PCI:

• Balloon angioplasty: Delay surgery 14 days 1, 2
• Bare-metal stent (BMS): Delay surgery 30 days 1, 2
• Drug-eluting stent (DES): Optimally delay surgery 365 days (Class I) 1, 2
• DES minimum: May consider surgery after 180 days if risk is acceptable (Class IIb) 1, 2

Critical warning: Do NOT perform elective surgery within 30 days of BMS or within 12 months of DES if DAPT must be discontinued (Class III: Harm) 1, 2, 4.

For urgent surgery in patients with recent stents (within 4-6 weeks):

• Continue DAPT unless bleeding risk outweighs stent thrombosis risk (Class I) 1, 2
• If P2Y12 inhibitor must be stopped, continue aspirin and restart P2Y12 inhibitor as soon as possible after surgery (Class I) 1, 2

Anticoagulation Management

Use a multidisciplinary team-based approach for time-based interruption of oral anticoagulants 5.

For DOACs (apixaban, rivaroxaban, edoxaban, dabigatran):

• High bleeding risk procedures: Hold 2-3 days preoperatively depending on renal function 5
• Low/moderate bleeding risk: Hold 1-2 days preoperatively 5
• Minimal bleeding risk: No interruption needed 5

For warfarin:

• Stop 5 days before high bleeding risk procedures 5
• Routine perioperative bridging is NOT recommended (Class 3) due to increased bleeding risk 5
• Bridging with parenteral heparin can be effective only in high thrombotic risk patients (e.g., mechanical mitral valve, recent stroke, CHA2DS2-VASc ≥7) undergoing procedures requiring VKA interruption (Class IIa) 5

Resume anticoagulation after hemostasis is achieved 5.

Common Pitfalls

1. Starting beta blockers on the day of surgery: This significantly increases stroke and mortality risk 1, 3
2. Routine prophylactic coronary revascularization: Not recommended before noncardiac surgery in stable CAD (Class III: No Benefit) 1, 2
3. Operating too soon after stent placement: Stent thrombosis risk is catastrophic—respect the timing guidelines 1, 2
4. Routine heparin bridging: Increases bleeding without clear benefit in most patients 5
5. Routine aspirin use: Does not reduce events but increases bleeding in most surgical patients without stents 3